A novel low-cost assay sequencing cell-free DNA methylome in blood demonstrates strong performance across a range of clinical applications.
A new study suggests that a single blood sample could soon detect multiple cancers, including liver, stomach, and lung cancer ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer. Heterogeneity and ...
"DELFI is tackling one of the most important unmet needs in oncology, and the combination of a differentiated fragmentomics platform, an integrated AI approach, a clear path to FDA approval and broad ...
Study: Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Image Credit: 3dMediSphere / Shutterstock In a recent study published in the ...
Circulating tumor DNA (ctDNA) can be detected in plasma samples sometimes several years prior to a clinical diagnosis of cancer, according to research ...
When cells in the body die, they release DNA. This DNA, known as cell-free DNA (cfDNA), makes its way into the bloodstream where it gets chopped up by enzymes, and in minutes to hours, the liver pulls ...
Ebihara Takashi has been the chief operating officer of GeneFrontier (GFC) since 2010, with a focus on advancing cell-free protein expression technologies, particularly the PURE system. He earned a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results